Antialdosterones: Incidence and prevention of sexual side effects

Degnbol, 1973, The effect of different diuretics on elevated blood pressure and serum potassium, Acta med. scand., 193, 407, 10.1111/j.0954-6820.1973.tb10601.x Berglund, 1976, Low doses of hydrochlorothiazide in hypertension. Anithypertensive and metabolic effects, Eur. J. clin. Pharmac., 10, 177, 10.1007/BF00558326 Bengtsson, 1975, Effect of different doses of chlorthalidone on blood pressure, serum potassium and serum urate, Br. med. J., 1, 197, 10.1136/bmj.1.5951.197 Medical Research Working Party, 1987, J. clin. Pharmac., 27, 271, 10.1002/j.1552-4604.1987.tb03012.x Crane, 1970, Effect of spironolactone in hypertensive patients, Am. J. med. Sci., 260, 311, 10.1097/00000441-197012000-00001 Mantero, 1973, Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension, Clin. Sci. molec. Med., 45, 2195 Tobian, 1985, Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered, Hypertension, 7, I110, 10.1161/01.HYP.7.3_Pt_2.I110 Khaw, 1987, Dietary potassium and stroke-associated mortality. A 12 year prospective population study, N. Engt. J. Med., 316, 235, 10.1056/NEJM198701293160502 Robertson, 1982, Diuretics and potassium in the treatment of hypertension in preventive medicine in the coming decade, 243 Komel, 1983, Arterial steroid receptors and their putative role in the mechanism of hypertension, J. steroid Biochem., 19, 333, 10.1016/S0022-4731(83)80045-4 Falch, 1983, The effect of spironolactone on lipid, glucose and uric acid levels in blood long-term administration to hypertensives, Acta med. scand., 213, 27, 10.1111/j.0954-6820.1983.tb03684.x Jeunemaitre, 1987, Efficacy and tolerance of spironolactone in essential hypertension, Am. J. Cardiol., 60, 820, 10.1016/0002-9149(87)91030-7 Rose, 1977, Pathophysiology of spironolactone-induced gynecomastia, Am. Intern. Med., 87, 398, 10.7326/0003-4819-87-4-398 Miyatake, 1978, Increase serum oestrone and oestradiol following spironolactone administration in hypertensive men, Clin. Endocr., 9, 523, 10.1111/j.1365-2265.1978.tb01510.x Corvol, 1975, Antiandrogenic effect of spironolactones: mechanism of action, Endocrinology, 97, 52, 10.1210/endo-97-1-52 Bonne, 1974, Mode of spironolactone antiandrogenic action: inhibition of androstanolone binding to rat prostate androgen receptor, Molec. Cell. Endocr., 2, 59, 10.1016/0303-7207(74)90012-4 Ulmann, 1985, Assessment of the antimineralocorticoid effect of RU28318 in healthy men with induced exogenous and endogenous hypermineralocorticism, Eur. J. clin. Pharmac., 28, 521, 10.1007/BF00544063 Degoulet, 1980, Hypertension management: the computer as a participant, Am. J. Med., 68, 559, 10.1016/0002-9343(80)90306-X Feinstein, 1984, Current problems and future challenges in randomized clinical trials, Circulation, 70, 767, 10.1161/01.CIR.70.5.767 Lawrie, 1984, Spironolactone and propranolol in the management of idiopathic hypertension, Acta Ther., 10, 257 Ramsay, 1982, Clinical pharmacology and therapeutic use ofaldosterone antagonists, 335 de Gasparo, 1987, Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro, J. Pharmac. exp. Ther., 240, 650 Joss U., Whitebread S. E., Haenni H., Grob J., Biollaz M., Kalvoda J.: Steroidal aldosterone antagonists: increasing selectivity by 9α, 11α-epoxysubstitution. J. med. Chem. Submitted. Kawaga, 1960, Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spironolactone, Endocrinology, 67, 125, 10.1210/endo-67-1-125 Clauberg, 1930, Der biologische Test für das Corpus Luteum-Honnon, Klin. Wochenschr., 9, 2004, 10.1007/BF01720561 Kamata, 1987, Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives, J. med. Chem., 30, 1647, 10.1021/jm00392a022 Bittler, 1982, Synthesis of spirorenone. A novel highly active aldosterone antagonist, Angew. Chem. Int. Ed. Engl., 211, 696, 10.1002/anie.198206961 Losert, 1986, Mespirenone and other 15,16-Methylene-17-spironolactones, a new type of steroidal aldosterone antagonists, Arzneim.-Forsch. (Drug Res.), 36, 1583 Nickisch, 1987, Aldosterone antagonists. 2. New 7α-(acetylthio)-15,16-methylene spironolactones, J. med. Chem., 30, 1403, 10.1021/jm00391a023 Ramsay, 1986, Spironolactone and potassium canrenoate in normal man, Clin. Pharmac. Ther., 20, 167, 10.1002/cpt1976202167